Weiss Asset Management LP purchased a new position in shares of Amgen, Inc. (NASDAQ:AMGN) during the first quarter, HoldingsChannel reports. The institutional investor purchased 1,888 shares of the medical research company’s stock, valued at approximately $359,000.
Several other large investors also recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Amgen by 2.0% during the 4th quarter. BlackRock Inc. now owns 46,127,396 shares of the medical research company’s stock worth $8,979,621,000 after purchasing an additional 906,568 shares during the period. Oregon Public Employees Retirement Fund grew its stake in shares of Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after purchasing an additional 31,268,677 shares during the period. Northern Trust Corp grew its stake in shares of Amgen by 4.7% during the 4th quarter. Northern Trust Corp now owns 9,182,050 shares of the medical research company’s stock worth $1,787,470,000 after purchasing an additional 408,675 shares during the period. Geode Capital Management LLC grew its stake in shares of Amgen by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 8,850,224 shares of the medical research company’s stock worth $1,720,250,000 after purchasing an additional 482,760 shares during the period. Finally, Norges Bank acquired a new position in shares of Amgen during the 4th quarter worth $1,283,248,000. 77.23% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts have recently weighed in on the stock. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a research note on Tuesday, June 11th. Oppenheimer set a $210.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Friday, May 24th. Citigroup raised shares of Amgen from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $211.00 to $205.00 in a research note on Wednesday, May 22nd. Royal Bank of Canada reaffirmed a “neutral” rating and set a $192.00 price target on shares of Amgen in a research note on Tuesday, May 21st. Finally, Credit Suisse Group assumed coverage on shares of Amgen in a research note on Monday, May 20th. They set an “outperform” rating and a $208.00 price target on the stock. Ten investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Amgen presently has an average rating of “Buy” and a consensus target price of $208.35.
Shares of NASDAQ AMGN opened at $176.08 on Monday. The stock has a market capitalization of $107.40 billion, a P/E ratio of 12.23, a price-to-earnings-growth ratio of 2.14 and a beta of 1.13. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.53 and a current ratio of 2.77.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the Zacks’ consensus estimate of $3.45 by $0.11. The firm had revenue of $5.56 billion for the quarter, compared to analysts’ expectations of $5.55 billion. Amgen had a net margin of 34.00% and a return on equity of 71.02%. The firm’s revenue was up .1% on a year-over-year basis. During the same period in the prior year, the company earned $3.47 EPS. As a group, equities research analysts expect that Amgen, Inc. will post 13.91 earnings per share for the current year.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $193.18, for a total value of $386,360.00. Following the transaction, the director now directly owns 15,092 shares in the company, valued at approximately $2,915,472.56. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 6,000 shares of company stock worth $1,089,180. 0.25% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “1,888 Shares in Amgen, Inc. (NASDAQ:AMGN) Acquired by Weiss Asset Management LP” was posted by Enterprise Leader and is the sole property of of Enterprise Leader. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://theenterpriseleader.com/2019/06/17/1888-shares-in-amgen-inc-nasdaqamgn-acquired-by-weiss-asset-management-lp.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Read More: How to start trading in the forex market?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.